API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Following the completion of the transition of GLASSIA manufacturing, Kamada will transfer the product’s us biologics license application (BLA) to takeda.
Lead Product(s): Human Alpha 1 Proteinase Inhibitor
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Glassia
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 07, 2021